Investors, analysts to pay close attention to Valeant’s 1Q results

When Valeant Pharmaceuticals reports its first quarter earnings on June 7, investors and analysts will pay attention to the results, the Wall Street Journal reports. The newspaper wrote that people will be interested to know how Valeant plans on paying down its $32 billion debt load and whether the company can meet its projections of $2.3 billion to $2.4 billion in revenue and $1.18 to $1.43 in adjusted earnings per share.

Since August 2015, Valeant’s share price has decreased nearly 90 percent, the Journal notes, as the federal government questioned the company’s business practices.

Read the full story below: